Hepatic carcinosarcoma: evidence of polyclonal origin based on microsatellite analysis

Area of Science:

• Oncology
• Genetics
• Pathology

Background:

• Hepatic carcinosarcoma (HCS) is a rare and aggressive liver tumor.
• The clonal origin of HCS, specifically the hepatocellular carcinoma (HCC) and sarcoma components, remains unclear.
• Understanding the origin is crucial for diagnosis and treatment strategies.

Purpose of the Study:

• To determine the clonal origin of the hepatocellular carcinoma (HCC) and sarcoma components within hepatic carcinosarcoma (HCS).
• To investigate whether HCS arises from a single cell (monoclonal) or multiple cells (polyclonal).

Main Methods:

• Analyzed three HCS patient samples using immunohistochemistry for specific markers (Hep Par 1, CK18, CD10, vimentin).
• Employed microsatellite analysis, including loss of heterozygosity (LOH) and microsatellite instability (MSI), to assess genetic alterations.
• Calculated the fractional allelic loss (FAL) index to differentiate between monoclonal (FAL <30%) and polyclonal (FAL ≥30%) origins.

Main Results:

• Immunohistochemistry confirmed distinct expression patterns for HCC (Hep Par 1, CK18, CD10 positive; vimentin negative) and sarcoma (vimentin positive; Hep Par 1, CK18, CD10 negative) components.
• Microsatellite analysis revealed high frequencies of LOH and MSI at specific markers (D16S505, D17S831, D17S938).
• Fractional allelic loss (FAL) indices ranged from 33.3% to 55.6%, all exceeding the 30% threshold, indicating a polyclonal origin.

Conclusions:

• The findings strongly support a polyclonal origin for hepatic carcinosarcoma (HCS).
• Both hepatocellular carcinoma and sarcoma components appear to arise independently.
• This study provides critical insights into the complex cellular origins of HCS.